
|Videos|March 8, 2022
Management of dermatologic adverse events with apalutamide in prostate cancer
Author(s)Urology Times staff
“The majority of patients were able to stay on the dose of the apalutamide,” says Mario E. Lacouture, MD.
Advertisement
In this video, Mario E. Lacouture, MD, discusses the background, findings, and takeaways of the Journal of Urology study, “Dermatologic adverse events in prostate cancer patients treated with androgen receptor inhibitor apalutamide.” Lacouture is a dermatologist at Memorial Sloan Kettering Cancer Center in New York, New York.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Testosterone deficiency: FAQs from the AUA guideline
3
Joshua Lang, MD, MS, on integrating molecular biomarkers into clinical practice
4
Large registry study reports durable 10-year outcomes with focal therapy for prostate cancer
5












